A unique mechanism of action
The unique characteristics of the MP4OX compound create a combined effect that prevents the premature release of oxygen in the vascular system and also opens the capillary beds for perfusion and targeted oxygen delivery. This optimizes its therapeutic benefit for patients experiencing oxygen deprivation related to hemorrhagic shock by rapidly providing oxygen directly where it is needed most.
The MP4OX compound enhances the function of standard of care (including red blood cells). MP4 does not replace the important role red blood cells play in medicine today.
MP4OX is not meant to mimic or to replace the use of transfused blood or red blood cells. MP4OX is designed to improve the perfusion and oxygenation of ischemic tissues by traveling where red blood cells cannot reach and opening the vasculature for targeted oxygen delivery in the capillaries, working alongside red blood cells or other standard of care. Additionally, in clinical trials the maximum dosage for MP4OX is far less than the volume required in severe transfusion settings, making it inappropriate to consider MP4OX as a replacement for red blood cells.
MP4OX also does not replace the characteristics naturally unique to blood, including the ability to clot, to provide nutrients or to enable immune function. That is why we have developed a clinical approach to study MP4OX as an adjunct to red blood cells (or other standard of care).
By preventing the premature release of oxygen in the vascular system and by enhancing perfusion, oxygen can be delivered directly to ischemic tissues through the capillaries by enhanced oxygen delivery with the MP4OX compound.
Please click here for a short animation describing MP4OX's unique mechanism of action.